What is the recommended treatment for atopic dermatitis?

Treatment of Eczema (Atopic Dermatitis)

Start with a medium-potency topical corticosteroid (mometasone furoate 0.1% ointment or cream) applied twice daily to all affected areas for 2–4 weeks, combined with fragrance-free emollients applied to the entire body at least once daily. 1, 2

Initial Management: Acute Flare Control

First-Line Topical Anti-Inflammatory Therapy

• Medium-potency topical corticosteroids (mometasone furoate 0.1%, fluticasone propionate 0.05%, or prednicarbate 0.02%) are the first-line choice for most body areas in moderate-to-severe flares, applied twice daily for 2–4 weeks. 1, 2
• For facial or intertriginous areas, use low-potency agents (hydrocortisone 1% or alclometasone dipropionate 0.05%) to reduce the risk of skin atrophy. 1, 2
• Potent corticosteroids (e.g., betamethasone dipropionate) may be used for severe flares on the trunk or extremities, but limit use to ≤2 consecutive weeks to avoid atrophy. 2

Essential Barrier Restoration

• Apply fragrance-free moisturizers to the entire body at least once daily, preferably immediately after bathing—not just to affected areas. 1, 2
• Use urea- or glycerin-based moisturizers to enhance barrier restoration. 2
• Recommend soap-free cleansers and avoidance of hot showers to prevent further barrier disruption. 2

Pruritus Management

• For severe pruritus, a short course of sedating oral antihistamines (e.g., diphenhydramine or clemastine) taken at night only is appropriate—these work primarily through sedation rather than antipruritic effects. 2, 3
• Topical polidocanol cream or urea-containing lotions can provide itch relief. 2

Transition to Proactive Maintenance Therapy

After achieving flare control (typically 2–4 weeks), continue the medium-potency corticosteroid applied twice weekly (e.g., Monday and Thursday) to all previously affected areas, even when skin appears normal. 1, 2

Maintenance Regimen Details

• Maintain this twice-weekly regimen for 16–36 weeks, which reduces relapse risk approximately 7-fold (from ~58% to ~25%). 1, 2
• Daily emollient use must continue throughout the maintenance phase. 1, 2
• This proactive approach prevents the rapid relapse that occurs when anti-inflammatory treatment is stopped after visible clearance. 2

Steroid-Sparing Alternatives for Persistent Symptoms

• If burning or itching persists after 2 weeks of appropriate corticosteroid therapy, add topical tacrolimus 0.03% or 0.1% on non-steroid days (2–3 times weekly). 1, 2
• Topical calcineurin inhibitors (tacrolimus or pimecrolimus 1% cream) serve as steroid-sparing alternatives, especially for facial involvement. 1, 2
• Crisaborole (PDE-4 inhibitor) and ruxolitinib cream (JAK inhibitor) are FDA-approved for mild-to-moderate disease and provide additional non-steroidal options. 1, 4

Newer FDA-Approved Topical Options

For patients requiring non-steroidal alternatives, tapinarof cream and roflumilast cream are strongly recommended. 4

• Tapinarof cream is approved for adults and children ≥2 years with mild-to-moderate atopic dermatitis. 4
• Roflumilast cream is approved for adults and children ≥6 years with mild-to-moderate disease. 4
• Ruxolitinib cream (topical JAK1/JAK2 inhibitor) significantly improves disease severity and pruritus with a comparable safety profile to vehicle. 1, 5

Escalation to Systemic Therapy

When moderate-to-severe atopic dermatitis persists despite optimized topical management after 2–4 weeks, escalate to systemic therapy. 1, 2

First-Line Systemic Agent

• Dupilumab (IL-4 receptor α antagonist) is the preferred first-line systemic agent, with all guideline workgroup members favoring it over other options. 1
• Dosing: 600 mg subcutaneously at initiation, then 300 mg every 2 weeks. 1
• Dupilumab has an excellent safety track record with no major emergent safety concerns after more than 5 years in clinical practice. 1
• No laboratory monitoring is required before initiation or during treatment. 1
• Conjunctivitis is a common adverse effect that should be discussed with patients. 1

Additional Biologic Options

• Tralokinumab (IL-13 antagonist): 600 mg at initiation followed by 300 mg every 2 weeks; somewhat less effective than dupilumab at 16 weeks but with no major safety concerns. 1
• Lebrikizumab (IL-13 inhibitor) is strongly recommended with concomitant topical therapy. 4
• Nemolizumab (IL-31 receptor antagonist) is strongly recommended with concomitant topical therapy, particularly effective for pruritus. 4, 6

JAK Inhibitors

• Upadacitinib and abrocitinib are oral JAK inhibitors approved for patients ≥12 years with moderate-to-severe disease. 1, 6
• These agents show comparable or superior efficacy to dupilumab at higher doses but require consideration of JAK inhibitor-class safety concerns. 1

Traditional Immunosuppressants (Off-Label)

• Cyclosporine (3–5 mg/kg/day) is effective but FDA-approved only for psoriasis; use is generally limited to 1 year due to toxicity concerns. 1
• Mycophenolate mofetil, azathioprine, and methotrexate have significant toxicity concerns and require intensive monitoring, making biologics preferred when injectable therapy is acceptable. 1, 3

Phototherapy

• Narrowband UVB phototherapy is recommended for chronic, inadequately controlled disease as the next therapeutic step before systemic agents. 1, 2

Critical Safety Considerations

Topical Corticosteroid Safety

• Never exceed 2 consecutive weeks of high-potency or very-potent corticosteroids due to atrophy risk. 2
• Do not apply corticosteroids more than twice daily; once-daily use of potent steroids is equally effective. 2
• Continuous daily application of topical corticosteroids for years markedly increases the risk of dermal atrophy, especially on flexural or intertriginous sites. 2
• Do not stop anti-inflammatory treatment when lesions appear cleared; cessation is the most common cause of rapid relapse. 2

Systemic Corticosteroid Avoidance

• Avoid systemic corticosteroids for maintenance therapy due to rebound flares upon discontinuation; reserve them only for short-term crisis management. 3

Monitoring and Reassessment

• Reassess patients after 2–4 weeks of therapy; if the condition worsens or shows no improvement, arrange referral to a dermatologist. 2
• For maintenance therapy extending beyond 36 weeks, transition to a tacrolimus-based proactive regimen to minimize long-term steroid exposure. 2
• Perform weekly self-monitoring for signs of steroid-related adverse effects (e.g., skin atrophy, telangiectasias, striae), especially on the face, neck, and body folds. 2

Common Pitfalls to Avoid

• Do not rely on emollients alone without scheduled anti-inflammatory therapy for recurrent disease; proactive steroid-based maintenance is superior. 2
• Do not continue high-potency steroids long-term, as they markedly increase the risk of skin atrophy, telangiectasias, and hypothalamic-pituitary-adrenal axis suppression. 2
• Do not apply steroids more than twice weekly during maintenance; higher frequency offers no additional benefit and raises side-effect risk. 2
• If symptoms persist after 2 weeks of appropriate therapy, assess for contact dermatitis to topical agents and consider patch testing. 2